Get the Stockscreener App
2.43
2.10%
0.05
After Hours:
2.43
Ac Immune Sa stock is traded at $2.43, with a volume of 172.12K.
It is up +2.10% in the last 24 hours and up +13.02% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$2.38
Open:
$2.37
24h Volume:
172.12K
Relative Volume:
1.28
Market Cap:
$244.00M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-3.4249
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
+6.58%
1M Performance:
+13.02%
6M Performance:
+4.74%
1Y Performance:
-20.33%
1-Day Range:
$2.31
$2.44
1-Week Range:
$2.16
$2.44
52-Week Range:
$1.4299
$3.98
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.43 | 241.44M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
How to recover losses in AC Immune SA stockMarket Trend Summary & Community Verified Trade Signals - Newser
AC Immune SA stock retracement – recovery analysisWall Street Watch & Low Risk Growth Stock Ideas - Newser
Analyzing recovery setups for AC Immune SA investorsJuly 2025 Setups & Technical Confirmation Trade Alerts - Newser
Has AC Immune SA formed a bullish divergenceJuly 2025 Catalysts & Community Verified Swing Trade Signals - Newser
What does recent volatility data suggest for AC Immune SAJuly 2025 PostEarnings & Community Verified Trade Signals - Newser
why ac immune sa is moving todayTrade Volume Report & Advanced Swing Trade Entry Plans - Newser
Why AC Immune SA is moving todayJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser
Real time social sentiment graph for AC Immune SAWeekly Trend Recap & Technical Confirmation Alerts - Newser
AC Immune SA stock daily chart insightsJuly 2025 Rallies & Daily Chart Pattern Signals - Newser
How to manage a losing position in AC Immune SAMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
AC Immune SA stock outlook for YEARJuly 2025 Levels & Low Risk High Reward Trade Ideas - Newser
Tick level data insight on AC Immune SA volatilityWeekly Trade Recap & Intraday High Probability Alerts - Newser
How to build a dashboard for AC Immune SA stock2025 Price Momentum & Weekly High Return Stock Forecasts - Newser
Visual trend scoring systems applied to AC Immune SAPortfolio Gains Report & Daily Technical Forecast Reports - Newser
AC Immune (NASDAQ:ACIU) Upgraded at Zacks Research - Defense World
Custom strategy builders for tracking AC Immune SA2025 Trading Recap & Long Hold Capital Preservation Tips - Newser
Real time scanner hits for AC Immune SA explained2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
How to forecast AC Immune SA trends using time seriesMarket Growth Summary & Breakout Confirmation Alerts - Newser
What indicators show strength in AC Immune SASwing Trade & Daily Price Action Insights - Newser
AC Immune SA Announces Strategic Focus and Workforce Reduction - MSN
Visual analytics tools that track AC Immune SA performanceTrade Exit Report & Safe Capital Growth Tips - Newser
BTIG Research Reaffirms Buy Rating for AC Immune (NASDAQ:ACIU) - MarketBeat
Volatility clustering patterns for AC Immune SA2025 Technical Patterns & Safe Entry Momentum Stock Tips - Newser
Order flow analysis tools used on AC Immune SAJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Forecasting AC Immune SA price range with options dataInsider Buying & Weekly Market Pulse Alerts - Newser
Advanced analytics toolkit walkthrough for AC Immune SAWeekly Volume Report & Entry Point Confirmation Signals - Newser
How to integrate AC Immune SA into portfolio analysis toolsWeekly Trend Report & AI Enhanced Execution Alerts - Newser
Can AC Immune SA weather a recessionForecast Cut & High Yield Stock Recommendations - Lancaster City Council
What is AC Immune SA’s book value per shareWeekly Trade Recap & AI Optimized Trading Strategy Guides - Lancaster City Council
Does AC Immune SA stock reflect fundamentals2025 EndofYear Setup & Growth Focused Investment Plans - Lancaster City Council
Identifying reversal signals in AC Immune SABuy Signal & Reliable Volume Spike Trade Alerts - Newser
Using data models to predict AC Immune SA stock movementWeekly Investment Report & Fast Momentum Entry Tips - Newser
Full technical analysis of AC Immune SA stockPortfolio Growth Summary & Long-Term Investment Growth Plans - Newser
Will AC Immune SA bounce back from current supportProduct Launch & High Return Trade Opportunity Guides - Newser
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):